Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Member
Base Pair BiotechnologiesBase Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.
Base Pair Biotechnologies specializes in custom aptamer discovery and development for research, diagnostics, therapeutics, and industrial applications. The company leverages proprietary multiplex selection, advanced bioinformatics, and chemical modification techniques to develop high-affinity and selective nucleic acid aptamers. Base Pair enables affinity reagent development, biosensor design, and molecular detection for a broad range of targets and partners across academia and industry.
Publication Number
US-10676781-B2
Publication Date
2020-06-09
Expiration Date
Abstract
The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules, such as tetrahydrocannabinol (THC).
Core Innovation
The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules, such as tetrahydrocannabinol (THC).
SELEX typically begins with a very large pool of randomized polynucleotides which is generally narrowed to one aptamer ligand per molecular target, and complex target arrays may generally be more expensive and/or difficult to make or utilize than solutions of target molecules. The invention addresses generating functional biomolecules against more than one or multiple targets simultaneously within a single system and marking or tagging binding members to match them to particular targets to enable high capacity, multiplexed identification procedures that may save time, expense, and physical space.
Claims Coverage
The claims include 1 independent claim and recite one inventive feature related to an artificial nucleic acid ligand to tetrahydrocannabinol.
Artificial ligand binding to tetrahydrocannabinol
An artificial ligand consisting essentially of a non-naturally occurring nucleic acid sequence having the sequence selected from the group consisting of SEQ IDs 75-84.
The independent claim is directed to an artificial non-naturally occurring nucleic acid ligand for THC defined by SEQ IDs 75-84.
Stated Advantages
May be utilized for detection, quantification, and/or other diagnostic applications, such as for detecting THC or its metabolites in body fluids or tissues, including blood, urine or saliva, for identifying THC usage in a person.
High capacity, multiplexed identification procedures may save time, expense, and physical space compared to single target identification processes.
May be utilized to identify and/or eliminate biomolecules that bind or have a tendency to bind to multiple targets and to resolve multiple binders to a single target.
Documented Applications
Use as sensors, therapeutic tools, to regulate cellular processes, and to guide drugs to their specific cellular target(s).
Detection, quantification, and other diagnostic applications for THC and its metabolites in body fluids or tissues, such as blood, urine or saliva, for identifying THC usage.
Use in detection formats including electrochemical sensors, gold nanoparticle assays, enzyme linked aptamer sorbent assays (ELASA), pull down assays (immunoprecipitation), microplate/well assays, and lateral flow assays.
Use as aptabeacons or molecular beacons that produce a detectable signal change (e.g., fluorescence) when the aptamer binds to its target.
Generating numerous different functional nucleic acids against multiple target molecules simultaneously, including affixing plurality of target molecules to a substrate in an array format and marking or tagging bound library members with identifier sequences for multiplexed selection and matching.
Use of histology sections as targets for generating affinity binding nucleic acids corresponding to specific locations on the section.
Use with peptide display and nucleic acid-tagging methods including phage display, mRNA display, and ribosome display to associate peptide binders with nucleic acid identifiers.
Interested in licensing this patent?